SIGRID
LIVE

Serial Number

97887000

Owner

Sigrid Therapeutics AB

Attorney

Bradley L. Cohn

Filing Date

Apr 13, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SIGRID Trademark

Serial Number: 97887000

SIGRID is a trademark filed by Sigrid Therapeutics AB on April 13, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

Sigrid Therapeutics AB (5 trademarks)

Birger Jarlsgatan 57

Entity Type: 98

Trademark Details

Filing Date

April 13, 2023

Registration Date

Not Registered

Published for Opposition

May 7, 2024

Goods & Services

Dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; pharmaceutical preparations and natural remedy preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemical pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietary and nutritional supplements; health food supplements for persons with special dietary requirements; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; dietary and nutritional supplements for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressure; dietary supplements for humans; dietary supplements for the support of healthy blood sugar levels, weight levels, cholesterol levels, blood pressure levels, and energy levels; vitamin supplements; mineral supplements; food supplements; nutritional supplements

Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated medical devices, and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, and post bariatric surgery patients

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2025 EXRA
SOU EXTENSION 3 GRANTED
Dec 9, 2025 EX3G
SOU EXTENSION 3 FILED
Dec 9, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 9, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jul 1, 2025 EX2G
SOU EXTENSION 2 FILED
Jul 1, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 1, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2024 EXRA
SOU EXTENSION 1 GRANTED
Oct 30, 2024 EX1G
SOU EXTENSION 1 FILED
Oct 30, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 30, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 2, 2024 NOAM
POST PUBLICATION AMENDMENT - ENTERED
Jun 26, 2024 CHPB
ASSIGNED TO PETITION STAFF
Jun 25, 2024 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 17, 2024 EPPA
PUBLISHED FOR OPPOSITION
May 7, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 7, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 17, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 7, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 4, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 9, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 8, 2023 NWOS
NEW APPLICATION ENTERED
Apr 17, 2023 NWAP